伦瓦提尼
医学
肝细胞癌
危险系数
肌萎缩
萎缩
内科学
胃肠病学
多元分析
癌
泌尿科
肿瘤科
置信区间
索拉非尼
作者
Masashi Fujita,Kazumichi Abe,Hidekatsu Kuroda,Takayoshi Oikawa,Masashi Ninomiya,Atsushi Masamune,Kazuo Okumoto,Tomohiro Katsumi,Wataru Sato,Katsunori Iijima,Tetsu Endo,Shinsaku Fukuda,Nobukazu Tanabe,Hiroshi Numao,Yasuhiro Takikawa,Yoshiyuki Ueno,Hiromasa Ohira
标识
DOI:10.1038/s41598-022-10514-3
摘要
Sarcopenia is associated with poor prognosis of patients with hepatocellular carcinoma (HCC). We investigated the association of skeletal muscle volume (SMV) and its change in HCC patients taking lenvatinib. In 130 HCC patients, psoas mass index (PMI) was calculated as the left-right sum of the major × minor axis of psoas muscle at the third lumbar vertebra, divided by height squared. Patients were classified into two groups (low and normal PMI) based on indices of < 6.0 cm2/m2 for man and < 3.4 cm2/m2 for women. Change in PMI per month during the lenvatinib administration period (ΔPMI/m) was calculated; and patients were classified into two groups (severe and mild atrophy) based on the ΔPMI/m rate, as ≥ 1% or < 1%, respectively. There was no significant difference in Overall survival (OS) between the low and normal PMI groups at the start of lenvatinib administration. OS was significantly lower in the severe atrophy group than in the mild atrophy group (median; 15.2 vs. 25.6 months, P = 0.005). Multivariate analysis revealed a significant association of severe atrophy with OS (hazard ratio 1.927, P = 0.031). Progressive loss of SMV is a strong predictor of poor prognosis in HCC patients taking lenvatinib.
科研通智能强力驱动
Strongly Powered by AbleSci AI